List of Bosulif drug patents
Bosulif is owned by Pf Prism Cv.
Bosulif contains Bosutinib Monohydrate.
Bosulif has a total of 5 drug patents out of which 0 drug patents have expired.
Bosulif was authorised for market use on 04 September, 2012.
Bosulif is available in tablet;oral dosage forms.
Bosulif can be used as a method of treating chronic myelogenous leukemia, a method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically effective amount of bosutinib, wherein the subject has a mutation in the bcrabl protein at 949t>c; a method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically effective amount of bosutinib, wherein the subject has a mutation in the bcrabl protein at f317l.
The generics of Bosulif are possible to be released after 28 February, 2034.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE42376 | PF PRISM CV | Substituted 3-cyanoquinolines |
Apr, 2024
(10 months from now) | |
| US7767678 | PF PRISM CV | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same |
Nov, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7919625 | PF PRISM CV | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
Dec, 2025
(2 years from now) | |
| US7417148 | PF PRISM CV | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
Dec, 2025
(2 years from now) | |
| US11103497 | PF PRISM CV | Treatment of imatinib resistant leukemia |
Feb, 2034
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Dec 19, 2024 |
Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient
Market Authorisation Date: 04 September, 2012
Treatment: A method of treating chronic myelogenous leukemia; A method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically...
Dosage: TABLET;ORAL
BOSULIF family patents
13
United States
6
European Union
5
Canada
5
Japan
4
Australia
3
Spain
3
Denmark
3
Poland
3
Russia
3
China
3
Brazil
3
Korea, Republic of
3
Portugal
3
Mexico
3
Slovenia
2
Panama
2
Hong Kong
2
Norway
2
Cyprus
2
Taiwan
2
Costa Rica
2
Ecuador
2
South Africa
1
Singapore
1
Argentina
1
Guatemala
1
Peru
1
Chile
1
Colombia
1
Hungary
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic